Lilly to change non-GAAP presentation; anticipates ~$165M IPR&D charge for Q1 2022, $0.15 EPS impact

ELI LILLY & Co

Will no longer adjust for upfront charges/development milestones on acquired IPR&D projects in non-GAAP measures.
Anticipates ~$165 million in such charges for Q1 2022, impacting EPS by ~$0.15.
Change follows SEC guidance; historical financials to be restated on company website.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.